Jemma Perks

Establishing non-inferiority of rituximab plus lenalidomide in the treatment of advanced previously untreated follicular lymphoma

Abstract Background and purpose The current standard of care for first-line treatment for people with advanced (stage 3 or 4) follicular lymphoma (FL) is chemotherapy plus rituximab. Rituximab plus lenalidomide is an oral treatment which has been shown to be an effective alternat...